Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;37(4):985-92.
doi: 10.2337/dc13-2097. Epub 2013 Nov 6.

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Lydia W Turner  1 , David Nartey, Randall S Stafford, Sonal Singh, G Caleb Alexander
Affiliations

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Lydia W Turner et al. Diabetes Care. 2014 Apr.

Abstract

OBJECTIVE Type 2 diabetes is increasingly common and associated with substantial morbidity and mortality. This study examines trends in the patterns and costs of drug treatment of type 2 diabetes from 1997 to 2012. RESEARCH DESIGN AND METHODS We conducted descriptive analyses of cross-sectional data using the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory physician practices in the U.S. We focused on visits for diabetes among patients 35 years of age or older. We used the IMS Health National Prescription Audit of pharmacy dispensing to derive information about drug expenditures. RESULTS Ambulatory diabetes visits increased from 23 million treatment visits in 1997 (95% CI 21-25) to 35 million (32-37) in 2007 and declined to 31 million visits by 2012 (27-31). Between 1997 and 2012 biguanide use increased, from 23% (20-26) to 53% (50-56) of treatment visits. Glitazone use grew from 6% (4-8) in 1997 (41% [39-43] of all visits in 2005), but declined to 16% (14-18) by 2012. Since 2005, dipeptidyl peptidase-4 (DPP-4) inhibitor use increased steadily, representing 21% (18-23) of treatment visits by 2012. Glucagon-like peptide 1 (GLP-1) agonists accounted for 4% of treatment visits in 2012. Visits where two or more drug compounds were used increased nearly 40% from 1997 to 2012. Between 2008 and 2012, drug expenditures increased 61%, driven primarily by use of insulin glargine and DPP-4 inhibitors. CONCLUSIONS Declining sulfonylurea and glitazone use has been offset by increases in DPP-4 inhibitor use and, to a lesser degree, use of GLP-1 agonists. Treatment of diabetes has grown in complexity while older treatments continue to be replaced or supplemented by newer therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
National trends in the ambulatory treatment of type 2 diabetes, 1997–2012. Source: NDTI, 1997–2012.
Figure 2
Figure 2
National trends in the ambulatory treatment of type 2 diabetes with insulins, 1997–2012. Source: NDTI, 1997–2012.
Figure 3
Figure 3
National trends in pharmacy expenditures on diabetes drugs, 2008–2012. Adjusted for inflation using 2008 dollars. Source: NPA, 2008–2012.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Diabetes Statistics. Data from the 2011 National Diabetes Fact Sheet (released January 26, 2011). Available from http://www.diabetes.org/diabetes-basics/diabetes-statistics/ Accessed 22 August 2013
    1. American Diabetes Association Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–1046 - PMC - PubMed
    1. Williams R, Van Gaal L, Lucioni C, CODE-2 Advisory Board Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002;45:S13–S17 - PubMed
    1. Alexander GC, Tseng CW. Six strategies to identify and assist patients burdened by out-of-pocket prescription costs. Cleve Clin J Med 2004;71:433–437 - PubMed
    1. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 2004;164:1134–1139 - PubMed

Publication types

Substances